June 19 World Sickle Cell Day celebrated around the world
Read the stories:
-
-
-
-
Chicago Woman Cured Of Sickle Cell Disease at 33
Chicagoan Ieshea Thomas is the first Midwest patient to receive a successful stem cell transplant to cure her sickle cell disease without chemotherapy in preparation for the transplant. University of Illinois Hospital & Health Sciences System physicians performed the procedure using medication to suppress her immune system and one small dose of total body radiation right before the transplant.
The transplant technique is relatively uncommon and is a much more tolerable treatment for patients with aggressive sickle cell disease who often have underlying organ disease and other complications, says Dr. Damiano Rondelli, professor of medicine at UIC, who performed Thomas's transplant.
The procedure initially allows a patient's own bone marrow to coexist with that of the donor. Since the patient's bone marrow is not completely destroyed by chemotherapy or radiation prior to transplant, part of the immune defense survives, lessening the risk of infection. The goal is for the transplanted stem cells to gradually take over the bone marrow’s role to produce red blood cells -- normal, healthy ones.
Thomas, 33, had her first sickle cell crisis when she was just 8 months old. Her disease became progressively worse as an adult, particularly after the birth of her daughter. She has spent most of her adult life in and out of hospitals with severe pain and has relied on repeated red blood cell transfusions. Her sickle cell disease also caused bone damage requiring two hip replacements.
"I just want to be at home with my daughter every day and every night," said Thomas, who depends on family to help care for her daughter during her frequent hospitalizations.
This type of stem cell transplant is only possible for patients who have a healthy sibling who is a compatible donor. Thomas' sister was a match and agreed to donate blood stem cells through a process called leukapheresis. Several days prior to leukapheresis, Thomas' sister was given drugs to increase the number of stem cells released into the bloodstream. Her blood was then processed through a machine that collects white cells, including stem cells. The stem cells were frozen until the transplant.
Last Nov. 23, four bags of frozen stem cells were delivered to the hospital's blood and marrow transplant unit. One by one, the bags were thawed and hung on an IV pole for infusion into Thomas. The procedure took approximately one hour. Her 13-year-old daughter, Miayatha, was at her bedside.
Six months after the transplant, Thomas is cured of sickle cell disease and no longer requires blood transfusions. "The donor cells have taken over completely, and blood tests show no sickle cell disease," said Rondelli, director of the blood and marrow transplant program at UI Hospital. Thomas continues to take medication to prevent rejection of the donor stem cells.
About 25 adults have received a similar chemotherapy-free stem cell transplant for sickle cell disease in recent years at the National Institutes of Health in Bethesda, Md. Approximately 85 percent have been cured.
"Sickle cell disease is devastating -- both emotionally and physically," said Dr. Dennis Levinson, a private rheumatologist in Chicago and clinical associate professor of medicine at UIC, who has taken care of Thomas for the past 16 years. "I've been terribly frustrated with Ieshea's disease over the years, and I've cared for many other sickle cell patients who have died."
Levinson says the stem cell transplant provides new hope for patients who often live day-to-day on painkillers and who are often misunderstood by clinicians. As the former chief of medicine at the now closed Michael Reese Hospital, he said he has cared for many patients with sickle cell anemia and was determined to seek out the best treatment option for Thomas.
Sickle cell disease primarily affects people of African descent. It is an inherited defect of the red blood cells that causes them to be shaped like a crescent, or sickle. These abnormal cells deliver less oxygen to the body's tissues and can result in severe pain, stroke and organ damage.
Approximately one in every 500 African Americans born in the U.S. has sickle cell disease. The disease affects 80,000 Americans of different ethnic backgrounds.
The University of Illinois Hospital & Health Sciences System provides comprehensive, life-long care for pediatric and adult sickle cell patients.
For more information, visit http://www.hospital.uillinois.edu.
[Editor's note: Video report available at http://youtu.be/E89xXeeby-A and photos available at http://newsphoto.lib.uic.edu/v/bone_marrow_transplant/.]
Children Stories needed from around the world
The authors of Hope & Destiny: The Patient and Parent's Guide to Sickle Cell Disease and Sickle Cell Trait are planning a children’s version and would like parents to send a short 1 page story written by their school aged child with sickle cell disease that would encourage a child with sickle cell in another country.. Any selected story will be published anonymously with the parent’s permission. There is no compensation, only the joy of being published: Send stories with your child’s age and initials to
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
New Web resource
National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention
2011 Annual Report on Sickle Cell Disease and Thalassemia at http://www.cdc.gov/ncbddd/AboutUs/blood-disorders-sicklecell.html
Video Resources
New CDC Videos Posted
2012-05-24 - Dr. Paula Tanabe, Duke University
Streaming Video : mms://realaudio.service.emory.edu/SOM/PA/PLATT/SICKLE/CDCertreat.wmv
PDF of Presentation Handout : Sickle Cell Disease and Emergency Department Use
2012-04-26 - Dr. Kathryn Hassell, University of Colorado Denver
Streaming Video : View Recording
PDF of Presentation Handout : Sickle Cell – Adult Providers Network
Schedule of Free CDC 2012 Webinars
“Public Health Webinar Series on Hemoglobinopathies”
Hosted by: The Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities (NCBDDD), Centers for Disease Control and Prevention (CDC) 4th Thursday of every month from 2:00PM – 3:00PM ET The purpose of this webinar series is to offer a hemoglobinopathies learning collaborative platform for providers, consumers, educators, and scientists.
This month’s webinar will take place on Thursday, June 28th from 2:00pm – 3:00pm ET, featuring
Dr. Lanetta Jordan’s presentation on “Sickle Cell Trait – What Every CBO Needs To Know”
Hemoglobinopathy Webinars are archived at http://scinfo.org
To Join The Webinar
Copy this address and paste it into your web browser: https://www.livemeeting.com/cc/cdc/join
Copy and paste the required meeting ID: 84QK2D and click “join”.
First Time Users: To save time before the meeting, check your system to make sure it is ready to use Microsoft Office Live Meeting. To hear the presentation you must call in to the number below.
For Audio
Dial 1-877-953-6706 and enter participant code: 9706616
If you are unable to join us on the internet for viewing, you are welcome to call in for audio access only. Participants outside the United States must be able to access 800 numbers to the US. Otherwise, please RSVP the location and number of participants for alternative international conference line access.
7/26: Improved Survival of Children and Adolescents with Sickle Cell Disease Dr. Charles Quinn, Cincinnati Children's Hospital Medical Center
8/23: Translating Research to Policy Dr. Shawn Bediako, University of Maryland, Baltimore County
9/27: Improving Quality of Care for Sickle Cell Pediatrics in the Emergency Department Dr. James Moses, Boston Medical Center
10/25: Strategies from the Field – Data Collection and Harmonization CDC’s Division of Blood Disorders and RuSH Project States
November/December: --- No Webinars---
See all the previous CDC Sickle Cell Webinars and instructions to view or listen to future events see: http://scinfo.org/world-wide-resources/cdc-webinars-hemoglobinopathies-and-public-health
Free ASH webinars
http://hematology.org/Meetings/Webinars/6832.aspx
Pain in Sickle cell disease and 
Stroke, Renal Disease, and Treatment with Hydroxyurea in Adults with Sickle Cell Disease
Articles in the Medical Literature for June
|
|
|
1.
|
Patient Educ Couns. 2012 May 31. [Epub ahead of print]
Bradford L , Roedl SJ , Christopher SA , Farrell MH .
Source
Center for Patient Care and Outcomes Research, Medical College of Wisconsin, Milwaukee, WI, USA.
Abstract
OBJECTIVE:
To examine the use of social support behaviors by primary care providers during delivery of positive newborn screening results for Sickle Cell Anemia carrier status.
METHODS:
Transcripts from 125 primary care providers who conveyed Sickle Cell Anemia carrier status to standardized parents were content analyzed using categories derived from Cutrona and Suhr's social support taxonomy. Frequencies and cross-tabulation matrices were calculated to study providers' social support utilization.
RESULTS:
Results showed most primary care providers (80%) incorporate social support behaviors into delivery of Sickle Cell Anemia carrier results and most frequently employed social network (61.6%) and informational support (38.4%) behaviors. Providers used tangible aid (8%), esteem (1.6%), and emotional support (9.6%) behaviors less frequently.
CONCLUSION:
Cutrona and Suhr's taxonomy may be a useful tool for assessing supportive communication during the delivery of Sickle Cell Anemia carrier status and could be incorporated into population scale assessments of communication quality assurance.
PRACTICE IMPLICATIONS:
Primary care providers may need training in how to adapt supportive behaviors to parents' needs during communication of Sickle Cell Anemia carrier status. They also may benefit from specific training about how to use esteem and emotional support.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.
|
|
PMID: 22658247 [PubMed - as supplied by publisher]
|
|
Related citations
|
|
|
|
2.
|
Anemia. 2012;2012:428137. Epub 2012 May 14.
Makala L , Di Maro S , Lou TF , Sivanand S , Ahn JM , Pace BS .
Source
Department of Pediatrics, Georgia Health Sciences University, Augusta, GA 30912, USA.
Abstract
Fetal hemoglobin (HbF) improves the clinical severity of sickle cell disease (SCD), therefore, research to identify HbF-inducing agents for treatment purposes is desirable. The focus of our study is to investigate the ability of FK228 analogues to induce HbF using a novel KU812 dual-luciferase reporter system. Molecular modeling studies showed that the structure of twenty FK228 analogues with isosteric substitutions did not disturb the global structure of the molecule. Using the dual-luciferase system, a subgroup of FK228 analogues was shown to be inducers of HbF at nanomolar concentrations. To determine the physiological relevance of these compounds, studies in primary erythroid progenitors confirmed that JMA26 and JMA33 activated HbF synthesis at levels comparable to FK228 with low cellular toxicity. These data support our lead compounds as potential therapeutic agents for further development in the treatment of SCD.
PMCID: PMC3359661 Free PMC Article
|
|
PMID: 22655179 [PubMed - in process]
|
|
Related citations
|
|
 
|
|
3.
|
Am J Respir Crit Care Med. 2012 Jun 7. [Epub ahead of print]
Desai AA , Zhou T , Ahmad H , Zhang W , Mu W, Trevino S , Wade MS , Raghavachari N , Kato GJ , Peters-Lawrence MH , Thiruvoipati T , Turner K , Artz N , Huang Y , Patel AR , Yuan JX , Gordeuk VR , Lang RM , Garcia JG , Machado RF .
Source
Medicine, University of Illinois at Chicago, Chicago, Illinois, United States.
Abstract
RATIONALE:
Pulmonary hypertension defined by right heart catheterization and an increased tricuspid regurgitation jet velocity (TRV≥2.5m/s) on transthoracic echocardiography both independently confer increased mortality in sickle cell disease.
OBJECTIVE:
We explored the utility of peripheral blood mononuclear cell-derived gene signatures as biomarkers for an elevated tricuspid regurgitation jet velocity in sickle cell disease. Methods &
MEASUREMENTS:
Twenty-seven sickle patients underwent echocardiography and of peripheral blood mononuclear cell isolation for expression profiling and 112 sickle patients were genotyped for SNPs.
MAIN RESULTS:
Genome-wide gene and miRNA expression profiles were correlated against tricuspid regurgitation velocity, yielding 631 transcripts and 12 miRNAs. Support vector machine analysis identified a 10-gene signature including GALNT13 (encoding polypeptide N-acetylgalactosaminyltransferase 13) that discriminates patients with and without increased TRV with 100% accuracy. This finding was then validated in a cohort of sickle patients without (n=10) and with pulmonary hypertension (n=10, 90% accuracy). Increased tricuspid regurgitation velocity-related miRNAs revealed strong in silico binding predictions of miR-301a to GALNT13 corroborated by microarray analyses demonstrating an inverse correlation between their expression. A genetic association study comparing patients with an elevated (n=49) versus normal (n=63) tricuspid regurgitation velocity revealed 5 significant SNPs within GALNT13 (p<0.005), four trans-acting (p<2.1e-07) and one cis-acting (p=0.6e-04) expression quantitative trait loci (eQTLs) upstream of the adenosine-A2B receptor gene (ADORA2B).
CONCLUSION:
These studies validate the clinical utility of genomic signatures as potential biomarkers and highlight ADORA2B and GALNT13 as potential candidate genes in sickle-associated elevated tricuspid regurgitation velocity.
|
|
PMID: 22679008 [PubMed - as supplied by publisher]
|
|
Related citations
|
|
|
|
4.
|
Hemoglobin. 2012 Jun 19. [Epub ahead of print]
Jain DL , Sarathi V , Upadhye D , Gulhane R , Nadkarni AH , Ghosh K , Colah RB .
Source
Department of Paediatrics, Government Medical College , Nagpur-440009 , India.
Abstract
There is limited data on the incidence of sickle cell anemia in Central India; we therefore conducted a study to estimate the incidence of this disease in Central India. Mothers who delivered a live baby at the Government Medical College, Nagpur, India were screened for the presence of the sickle cell hemoglobin {Hb S: [β6 (A3) Glu →Val, GAG >GTG]} using the solubility test within 48 hours of delivery. Infants of mothers who showed the presence of Hb S then underwent Hb analysis by high performance liquid chromatography (HPLC). A total of 8243 mothers was screened, 1178 of whom were positive. One thousand, one hundred and sixty-two infants of mothers with a positive solubility test underwent Hb analysis by HPLC; 530 infants were normal, while 536 were heterozygous for Hb S (sickle cell trait), 88 babies were homozygous for Hb S (sickle cell anemia), while another eight babies had other Hb abnormalities. The incidence of sickle cell anemia was highest in the Scheduled caste group (1:50). We concluded that the incidence of sickle cell anemia is high in central India.
|
|
PMID: 22712682 [PubMed - as supplied by publisher]
|
|
Related citations
|
|
|
|
5.
|
Infect Genet Evol. 2012 Jun 12. [Epub ahead of print]
Penman BS , Gupta S , Buckee CO .
Source
Department of Zoology, University of Oxford, UK.
Abstract
Genetic disorders of haemoglobin (haemoglobinopathies), including the thalassaemias and sickle cell anemia, abound in historically malarious regions, due to the protection they provide against death from severe malaria. Despite the overall spatial correlation between malaria and these disorders, inter-population differences exist in the precise combinations of haemoglobinopathies observed. Greece and Italy present a particularly interesting case study: their high frequencies of beta thalassaemia speak to a history of intense malaria selection, yet they possess very little of the strongly malaria protective mutation responsible for sickle cell anemia, despite historical migrational links with Africa where high frequencies of sickle cell occur. Twentieth century surveys of beta thalassaemia and sickle cell in Greece, Sicily and Sardinia have revealed striking sickle cell 'hotspots' - places where the frequency of sickle cell approaches that seen in Africa while neighboring populations remain relatively sickle cell free. It remains unclear how these hotspots have been maintained over time without sickle cell spreading throughout the region. Here we use a metapopulation model to show that (i) epistasis between the alpha and beta forms of thalassaemia can restrict the spread of sickle cell through a network of linked subpopulations, and (ii) the emergence of sickle cell hotspots requires relatively low levels of gene flow, but the aforementioned epistasis increases the chances of hotspots forming.
Copyright © 2012. Published by Elsevier B.V.
|
|
PMID: 22704979 [PubMed - as supplied by publisher]
|
|
Related citations
|
|
|
|
6.
|
Cytokine. 2012 Jun 14. [Epub ahead of print]
Hyacinth HI , Gee BE , Adamkiewicz TV , Adams RJ , Kutlar A , Stiles JK , Hibbert JM .
Source
Genomics and Hemoglobinopathies Training Program, Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, 720 Westview Drive SW, Atlanta, GA, USA.
Abstract
Sickle cell anemia (SCA) associated cerebrovascular disease includes vascular remodeling, abnormal cerebral blood flow (CBF) and infarction. We studied the relationships between plasma brain derived neurotropic factor (BDNF), platelet derived growth factors (PDGF-AA and -AB/BB) and high trans-cranial Doppler (TCD) velocity as an indication of CBF velocity. Baseline plasma samples from 39 children (19 SCA with abnormal/high TCD [SATCD], 13 SCA with normal TCD [SNTCD] and 7 healthy non-SCA), were assayed for BDNF, PDGF-AA and -AB/BB plus 11 other cytokines. The sensitivity, specificity and usefulness of these biomarkers for stroke prediction was investigated. All subject groups were of similar age and gender distribution. Mean BDNF was significantly higher among SATCD than SNTCD (p=0.004) as was mean PDGF-AA (p=0.001). Similarly, mean PDGF-AA was higher among SCA subjects who developed stroke than those who did not (p=0.012). Elevated BDNF and PDGF-AA were good predictors of the presence of abnormally high CBF velocity and were both associated with severity of anemia. Elevated PDGF-AA predicted risk for stroke development. Stroke incidence and high TCD velocity were associated with elevated BDNF and PDGF-AA. These findings suggest a role for BDNF and PDGF-AA in the patho-physiological mechanism of cerebrovascular disease in SCA.
Copyright © 2012 Elsevier Ltd. All rights reserved.
|
|
PMID: 22704695 [PubMed - as supplied by publisher]
|
|
Related citations
|
|
|
|
7.
|
Anemia. 2012;2012:492428. Epub 2012 Jun 4.
Crosby LE , Barach I , McGrady ME , Kalinyak KA , Eastin AR , Mitchell MJ .
Source
College of Medicine, University of Cincinnati, Cincinnati, OH 45221, USA.
Abstract
Research indicates that the quality of the adherence assessment is one of the best predictors for improving clinical outcomes. Newer technologies represent an opportunity for developing high quality standardized assessments to assess clinical outcomes such as patient experience of care but have not been tested systematically in pediatric sickle cell disease (SCD). The goal of the current study was to pilot an interactive web-based tool, the Take-Charge Program, to assess adherence to clinic visits and hydroxyurea (HU), barriers to adherence, solutions to overcome these barriers, and clinical outcomes in 43 patients with SCD age 6-21 years. Results indicate that the web-based tool was successfully integrated into the clinical setting while maintaining high patient satisfaction (>90%). The tool provided data consistent with the medical record, staff report, and/or clinical lab data. Participants reported that forgetting and transportation were major barriers for adherence to both clinic attendance and HU. A greater number of self-reported barriers (P < .01) and older age (P < .05) were associated with poorer clinic attendance and HU adherence. In summary, the tool represents an innovative approach to integrate newer technology to assess adherence and clinical outcomes for pediatric patients with SCD.
PMCID: PMC3372407 Free PMC Article
|
|
PMID: 22701785 [PubMed - in process]
|
|
Related citations
|
|
|
|
8.
|
Ultrasound Med Biol. 2012 Jun 12. [Epub ahead of print]
Doepp F , Kebelmann-Betzing C , Kivi A , Schreiber SJ .
Source
Department of Neurology, University Hospital Charité, Berlin, Germany.
Abstract
Increased blood flow velocity (BFV) in basal cerebral arteries measured by transcranial color-coded sonography (TCCS) is a stroke risk factor in sickle cell disease (SCD). Raised BFV may be caused by vessel narrowing or by hyperperfusion. In 44 SCD patients and 14 controls, intracranial arterial BFVs and global cerebral blood flow (CBF) were analyzed by TCCS and extracranial duplex ultrasound, respectively. Magnetic resonance imaging and magnetic resonance angiography were performed in all patients with pathologic intracranial BFV rise. Intracranial BFVs and CBF in SCD were significantly higher than in controls. CBF in SCD correlated with BFV in all intracranial arteries and correlated inversely with age and hemoglobin values. Magnetic resonance angiography failed to demonstrate any stenosis in our SCD patients, thus raised intracranial BFVs must be interpreted as an anemia-dependent cerebral hyperperfusion. These findings suggest that the pathomechanism of stenosis-derived arterio-arterial embolism might be less relevant in SCD-related ischemic stroke, and other factors like small vessel disease or sickle cell-induced microvascular blood clotting have to be considered.
Copyright © 2012 World Federation for Ultrasound in Medicine & Biology. Published by Elsevier Inc. All rights reserved.
|
|
PMID: 22698503 [PubMed - as supplied by publisher]
|
|
Related citations
|
|
|
|
9.
|
Cochrane Database Syst Rev. 2012 Jun 13;6:CD005406.
Okomo U , Meremikwu MM .
Source
Viral Diseases Programme, Medical Research Council (UK), Atlantic Boulevard, Fajara, Gambia, P.O. Box 273.
Abstract
BACKGROUND:
Treating vaso-occlusive painful crises in people with sickle cell disease is complex and requires multiple interventions. Extra fluids are routinely given as adjunct treatment, regardless of the individual's state of hydration with the aim of slowing or stopping the sickling process and thereby alleviating pain.
OBJECTIVES:
To determine the optimal route, quantity and type of fluid replacement for people with sickle cell disease with acute painful crises.
SEARCH METHODS:
We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register which comprises of references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings.We also conducted searches of EMBASE (November 2007), LILACS and www.ClinicalTrials.gov (05 January 2010).Date of most recent search of the Group's Haemoglobinopathies Trials Register: 09 February 2012.
SELECTION CRITERIA:
Randomised and quasi-randomised controlled trials that compared the administration of supplemental fluids adjunctive to analgesics by any route in people with any type of sickle cell disease during an acute painful episode, under medical supervision (inpatient, day care or community).
DATA COLLECTION AND ANALYSIS:
No relevant trials have yet been identified.
MAIN RESULTS:
Sixteen trials were identified by the initial search. Of these, 15 were not suitable for inclusion in this review and one study is awaiting further assessment.
AUTHORS' CONCLUSIONS:
Treating vaso-occlusive crises is complex and requires multiple interventions. Extra fluids, generally oral or intravenous, are routinely administered during acute painful episodes to people with sickle cell disease regardless of the individual's state of hydration. Reports of their use during these acute painful episodes do not state the efficacy of any single route, type or quantity of fluid compared to another. However, there are no randomised controlled trials that have assessed the safety and efficacy of different routes, types or quantities of fluid. This systematic review identifies the need for a multicentre randomised controlled trial assessing the efficacy and possible adverse effects of different routes, types and quantities of fluid administered to people with sickle cell disease during acute painful episodes.
|
|
PMID: 22696351 [PubMed - in process]
|
|
Related citations
|
|
|
|
10.
|
Acad Emerg Med. 2012 Jun;19(6):664-72. doi: 10.1111/j.1553-2712.2012.01364.x.
Glassberg JA , Wang J , Cohen R , Richardson LD , Debaun MR .
Source
From the Department of Emergency Medicine (JG, LDR) and the Department of Health Evidence and Policy (JW), Mount Sinai School of Medicine, New York, NY; Pediatrics, Drexel University College of Medicine, Division of Pediatrics, and St. Christopher's Hospital for Children (RC), Philadelphia, PA; and the Departments of Pediatrics and Medicine, Vanderbilt Children's Hospital (MRD), Nashville, TN.
Abstract
ACADEMIC EMERGENCY MEDICINE 2012; 19:664-672 © 2012 by the Society for Academic Emergency Medicine ABSTRACT: Objectives: The objective was to identify clinical, social, and environmental risk factors for increased emergency department (ED) use in children with sickle cell disease (SCD). Methods: This study was a secondary analysis of ED utilization data from the international multicenter Silent Cerebral Infarct Transfusion (SIT) trial. Between December 2004 and June 2010, baseline demographic, clinical, and laboratory data were collected from children with SCD participating in the trial. The primary outcome was the frequency of ED visits for pain. A secondary outcome was the frequency of ED visits for acute chest syndrome. Results: The sample included 985 children from the United States, Canada, England, and France, for a total of 2,955 patient-years of data. There were 0.74 ED visits for pain per patient-year. A past medical history of asthma was associated with an increased risk of ED utilization for both pain (rate ratio [RR] = 1.28, 95% confidence interval [CI] = 1.04 to 1.58) and acute chest syndrome (RR = 1.60, 95% CI = 1.03 to 2.49). Exposure to environmental tobacco smoke in the home was associated with 73% more ED visits for acute chest syndrome (RR = 1.73, 95% CI = 1.09 to 2.74). Each $10,000 increase in household income was associated with 5% fewer ED visits for pain (RR = 0.95, 95% CI = 0.91 to 1.00, p = 0.05). The association between low income and ED utilization was not significantly different in the United States versus countries with universal health care (p = 0.51). Conclusions: Asthma and exposure to environmental tobacco smoke are potentially modifiable risk factors for greater ED use in children with SCD. Low income is associated with greater ED use for SCD pain in countries with and without universal health care.
© 2012 by the Society for Academic Emergency Medicine.
PMCID: PMC3375948 [Available on 2013/6/1]
|
|
PMID: 22687181 [PubMed - in process]
|
|
Related citations
|
|
Sickle Cell Conferences and Events
July 5-7, 2012 Venetian / Palazzo Hotel Las Vegas - Association of Nigerian Physicians in the Americas
“The 18th Annual ANPA Convention & Scientific Assembly will be held July 5-7, 2012 at the Venetian / Palazzo Hotel in Las Vegas, Nevada. The theme for this year’s assembly will be “Righting the Wrong in Sickle Cell Disease”, and “Information Technology in Medical Practice”. The ANPA Annual Meeting features three full-day meetings, providing participants’ knowledge related to the challenges facing minority health care providers in the provision of clinical and therapeutic services for diseases and conditions related to a variety of medical specialties. The meeting will feature member lecturers providing state of the art technological advances that will impact the practice of medicine. The annual convention is of great value to our membership and other health care professionals by providing them with opportunities to keep abreast of developments in various areas of health care delivery and also offering continuing medical education (CME) credits. For more information please visit www.anpa.org or call 913.402.7102. “
September 25 – 29, 2012 The Sickle Cell Disease Association of America 40th Annual Conference Baltimore MD
The conference will be held September 25 – 29, 2012 at the Baltimore Marriott Waterfront Hotel in Baltimore, MD. We promise that this will be one of the most educational and empowering events to take place within the sickle cell community! http://www.sicklecelldisease.org/index.cfm?page=annual-convention
|
News 
